Background. Diabetes mellitus (DM) is a prevalent disease that, if not appropriately managed, can lead to a variety of problems, including diabetic foot. Glycated hemoglobin A1c (HbA1c), FBS, amylase, and lipase are important diabetic management indicators now employed as diagnostic tests. Objective. This study aimed to evaluate the value of amylase and lipase as predictive markers in patients with diabetic foot. Patients and methods. This study included 50 patients who reported to Baghdad Hospital with diabetic feet between November 2023 and February 2025. All patients had their HbA1c, amylase, lipase, and FBS levels tested. Means, independent t-tests, and the F-test were used in the statistical analysis. Results. The study evaluated 50 patients aged 35–75, revealing significant differences (p = 0.001). These findings underscore the potential of amylase and lipase as crucial prognostic markers in diabetic foot patients. People with diabetic feet had a high percentage of HbA1c and FBS and a substantial drop in amylase and lipase measures, with a difference value of (p = 0.001). Conclusion. The study's findings highlight the importance of HbA1c, amylase, and lipase as significant prognostic factors in diabetic foot patients. Levels exceeding 8 were associated with a poor prognosis and prolonged hospitalization, emphasizing the critical role of diabetes management in preventing and treating diabetic complications.
